The pharmacokinetics of clotting factor therapy.
Clotting factor preparations are expensive and not readily available in all parts of the world. We are still facing shortages due to limited production. Thus, it is obvious that clotting factor therapy should be optimised as far as possible. The judicious use of pharmacokinetic principles should be one of the fundaments of dosing. There are several pitfalls in studies of clotting factor pharmacokinetics, such as discrepancies between assays, inadequate blood sampling protocols, problems to define the administered dose, uncertainty in the estimation of plasma volume for in vivo recovery calculation, and post-infusion activation of the clotting factor. Thus, while the pharmacokinetics of factor VIII is well characterised there are some discrepancies in the literature on factor IX. Recombinant factor VIIa is useful to treat haemorrhages in haemophilia complicated by inhibitors. The pharmacokinetics of VIIa has been investigated, however, the relationship between plasma level of VIIa and effect needs further exploration. Important applications of clotting factor pharmacokinetics include optimising the treatment and improving its cost-effectiveness during long-term prophylaxis as well as during bleeding episodes and surgery.
Berntorp
E
E
Department of Coagulation Disorders and Hospital Pharmacy, Malmö University Hospital, Malmö, Sweden. erik.berntorp@medforsk.mas.lu.se
Björkman
S
S
D001779:Blood Coagulation Factors / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005164:Factor IX / Q000493:pharmacokinetics; D005169:Factor VIII / Q000493:pharmacokinetics; D015942:Factor VIIa / Q000493:pharmacokinetics; D006467:Hemophilia A / Q000097:blood*; D002836:Hemophilia B / Q000097:blood*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX; D015942:Factor VIIa